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Summary Thirty-one patients with stage ilA (N2) non-small-cell lung cancer were randomized to receive radiotherapy alone or
chemotherapy with cisplatin and vinblastine followed by surgery. Response rates to induction chemotherapy and radiotherapy were 50% and
53.3% respectively. Complete surgical resection was possible for 62.5% of patients. Median survival times were 16.2 and 18.7 months for
radiotherapy alone and chemotherapy-surgery respectively (P= Ns), with no long-term improvement in survival seen with combined-modality
treatment.
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Until recently. standard treatment for patients with stage III non-
small-cell lung cancer (NSCLC) has been thoracic irradiation
alone. The addition of systemic chemotherapy to radiotherapy
results in a modest improvement in median survival. but 5-year
survival remains less than 15% (Stewart. 1995). The combination
of induction chemotherapy and surgery for stage III NSCLC has
been assessed in several phase H studies. all of which have
confirmed the safety and feasibility of this approach (Shepherd.
1993: Albain. 1993). Most investigators report 5-year survival
rates ofapproximately 25%.
To determine whether this apparent improvement in survival
truly was due to combined-modality treatment with surgery rather
than to patient selection bias. the National Cancer Institute of
Canada Clinical Trials Group (NCIC-CTG) initiated a randomized
trial of thoracic irradiation alone vs induction chemotherapy and
surgery for patients with stage hIA NSCLC. The trial closed
prematurely when the Radiation Therapy Oncology Group study
88-08 showed a 31% 2-year survival rate for chemo-radiotherapy
compared with 20% for radiation alone (Sause et al. 1995). It was
felt by Canadian investigators that a radiation-alone control arm
was no longer appropriate. However. important observations have
arisen from the study that have relevance to ongoing trials of
combined-modality therapy in the UK and North America.
PATIENTS AND METHODS
Patients were required to have stage IIIA NSCLC with biopsy-
proven mediastinal node involvement. Stage HIB patients were
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excluded. They had to be able to tolerate the planned surgery and
have a post-operative predicted FEV-1 greater than 0.8 1. All
patients had to have an ECOG performance status < 2. baseline
haemoglobin > 100 A-' 1. granulocytes > 2.0 x 10 1-'. platelets
> 100 x 10 1-1. serum creatimine < 150 jmol 1-' and liver enzymes
< 1.25 x the upper limit of normal. The protocol Aas approved by
the Human Experimentation Committee ofeach institution. and all
patients gave informed consent.
Chemotherapy and surgery arm
Patients received cisplatin 120 mg m-' on days 1 and 29 and
vinblastine 6 mg m-' on days 1. 15. 22. 29 and 43. Cisplatin was
administered in hospital with vigorous hydration and mannitol
diuresis. and dexamethasone. ondansetron and lorazepam were
given to prevent vomiting. Patients proceeded to surgery between
days 51 and 64 if they achieved partial or complete response. or
stable disease after chemotherapy. An attempt was made to excise
all tissue felt to have been involved before chemotherapy. and
radical lymph node dissection was required. Patients who had
complete resection received the same chemotherapy. starting 6
weeks post-operatively.
Radiotherapy arm
A total dose of60 Gy was planned to be riven as 2 Gv daily 5 days
a week with the dose prescribed to the centre of the target volume
(ICRU 29). The initial target volume (50 Gy) included the primary
tumour. and ipsilateral hilar. subcarinal. tracheobronchial and
paratracheal nodes. The reduced target volume (10 Gy) included
the tumour and involved nodes as determined by computerized
tomography ormediastinoscopy. The spinal cord dose was limited
to 48 Gy and real time review was performed.
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Figure 1 A comparison of survival for patients treated with radiotherapy
alone(-, n = 15) surgery. (-, n = 16)
Statistical considerations
Patients were stratified for squamous vs non-squamous pathology.
and clinically detectable (>1.5 cm) mediastinal nodes vs micro-
scopic involvement only. Survival was calculated from the date of
randomization until death or last follow-up.
RESULTS
As shown in Table 1. there were no significant differences between
the two groups for any baseline clinical prognostic factors.
Response to therapy
Sixteen patients started chemotherapy, and 14 were evaluable for
response. One stopped chemotherapy because oftoxicity, and one
was not reassessed before surgery. The clinical response rate was
50% (all partial responses). Thirteen patients underwent thoraco-
tomy (81.3%). Reasons for not 'proceeding to surgery included
progressive disease (1) and toxicity from chemotherapy (2). Ten
patients had complete surgical resections (62.5%); one had an
incomplete resection and two patients had unrespectable tumours.
No patient had a pathological complete response. Only eight
patients had post-operative chemotherapy. One patient refused.
three with unrespectable or progressive disease had radiation and
the rest had either intercurrent illnesses or persistent toxicity that
precluded chemotherapy.
The response rate to radiotherapy was 53.3% (five partial. three
complete responses). Only one patient discontinued treatment
early because ofprogressive disease.
Toxicity
Grade 3 and 4 haematological toxicity and nausea and vomiting
were confined to the patients who had chemotherapy. The median
nadir granulocyte and platelet counts were 0.2 x 109 1-1 (0.01-
2.3 x 109 1-') and 166 x 109 1-1 (85-269 x 109 1-' respectively.
Three patients had febrile neutropenia. but no patient suffered a
toxic death as a result of chemotherapy. One patient had grade 3
radiation pneumonitis. but none had grade 3 or 4 oesophagitis.
Post-operative complications included arrythmia (three patients),
prolonged ventilation (twopatients), and prolonged airleak. infec-
tion and atelectasis (one patient each).
Relapse and survival
There have been eight local and one systemic relapses in the
chemotherapy and surgery arm, and six local and four systemic
relapses in the radiation arm. Median survival for patients treated
with radiation was 16.2 months (CI 10.7-32.3 months). compared
with 18.7 months (CI 12.8-32 months) for those on combined-
modality therapy (Figure 1).
DISCUSSION
In both Europe and North America. induction chemotherapy
followed by surgery has gained widespread acceptance as a treat-
ment for stage L1A NSCLC despite an absence of clinical trial
data that document its superiority over thoracic irradiation, either
alone or combined with chemotherapy. There have been three
randomized trials of induction chemotherapy and surgery
published to date, but all three had surgery in both arms (Pass et al.
1992: Roth et al. 1994; Rosell et al, 1994). The lack of a non-
surgical control arm is a major weakness of these studies as most
patients with stage [HA NSCLC are not considered to have
tumours that are resectable for cure. even though they may be
technically resectable.
In one trial (Roth et al. 1994). surgery alone was compared with
induction chemotherapy followed by surgery. In the other two
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9 Itrials. surgery with post-operative radiation was compared with
induction chemotherapy followed by surgery (Pass et al. 1992) or
induction chemotherapy. surgery and post-operative radiotherapy
(Rosell et al. 1994). Despite variability in the choice of induction
chemotherapy and administration of thoracic irradiation. they all
had similar results. Both median and 3-year survival rates were
superior in the treatment arms that included chemotherapy. and the
differences were statistically significant in two trials (Rosell et al.
1994: Roth et al. 1994).
However. these two trials are not felt to be definitive for several
reasons. Both studies had only 60 patients each. and they suffered
from major imbalances in critical prognostic variables. In the
surgery-alone arm of the Roth study. 40%c of patients had stage
IIIB or IV tumours. and were not. therefore. even eligible for the
trial. In contrast. the chemotherapy-surgery arm had only 11c%
stage IIIB and no stage IV patients. This serious stage imbalance
alone could have accounted for much ofthe difference in outcome.
In the Rosell trial. both arms were balanced for stage and clinical
prognostic factors. However. in the non-chemotherapy group. 42%c
of patients had mutations of the K-ras gene. a recognized adverse
prognostic factor. Furthermore. even though nine patients (30%)
had T3NO tumours. survival in the surgery-alone arm was surpris-
ingly poor. with no patient surviving to 2 years.
Although these trials suggest that surgery with or without
radiotherapy may be inferior treatment for patients with stage
I11A NSCLC. they do not tell us that induction chemotherapy and
surgery is the best treatment. Several investigators have ques-
tioned whether surgery is necessary at all. and whether thoracic
irradiation. either alone or with chemotherapy. might be equiv-
alent. Our trial was designed to determine whether. in a homo-
geneous group of patients. chemotherapy and surgerv was
superior to thoracic irradiation alone. We felt that the lack oflong-
term benefit in most of the randomized trials of radiation with
or without chemotherapy was adequate justification for the
radiation-alone control arm. We also felt that prolongation ofonly
short-term or median survival should not be the goal of
combined-modality surgical treatment. and so our study was
designed initially to detect a doubling of 3-year survival from
12.5%7 to 25% and would have required 240 patients. Because of
early closure. our results clearly are not definitive. but the lack of
any trend towards improved survival with combined-modality
therapy should lead investigators to question more strongly
whether the survival advantage seen in the Roth and Rosell
studies might have been due to imbalances in critical prognostic
factors rather than to true superiority of chemotherapy and
surgery. In support of this are the results of a 47-patient study
from the Cancer and Acute Leukemia Group B (CALGB). in
which surgery and radiation was compared with chemotherapy
with etoposide and cisplatin followed by surgerv and radiation
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(Elias et al. 1997). The median survival of the patients in the
chemotherapy arm was only 19 months compared with 23 months
for the patients who did not receive chemotherapy (P = 0.64).
The results of the NCIC-CTG and CALGB trials suggest that
the optimal treatment for patients with stage IlRA NSCLC remains
unknown. and they emphasize the urgent need for continued
research in the area. The two active trials in the UK and North
America should be supported vigorously as their results will be
critical for definition of the optimal treatment and clarification of
the role ofsurgaery for this potentially curable subset of NSCLC.
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